EuroPCR 2022 was a very successful event for Vesalius. In parallel to presenting during the Innovators' Day, Vesalius solution was published in EuroIntervention, the Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions...

Dr Peter Skarsgard, Vesalius President and Chief Scientific Officer, will be presenting Vesalius TMVr solution during the Innovators Day at EuroPCR in Paris on May 19th, 2022.    We believe mitral valve repair for simple or complex degenerative mitral regurgitation,...

During the Access to Innovation 2022 event organized by Lifesciences BC on February 16 and 17, our Chief Operating Officer Vincent Ledoux will be speaking on a panel relating to using IP to scale companies. This conference brings together leaders from across academia,...

Vesalius team celebrated today 5 years of next generation engineering and advanced biomedical innovations. Advancing medicine and simplifying the treatment for Mitral Regurgitation is and will always be our priority.     

Calla TMVr System, our comprehensive transfemoral DMR solution, will be unveiled to the clinical community in a podium presentation in the Innovation Theatre on November 4, 3PM local time. Please come and check us out! The Transcatheter Cardiovascular Therapeutics...

For the fifth consecutive year, Vesalius has been selected to pitch during Invest In BC, a major and very select yearly event organized by Life Sciences British Columbia and presented by Lumira Ventures.  Over two days, November 3rd and 4th, the event will bring...

The Vesalius Team joins the 2021 Vancouver Sun Run Virtual Race. This year, due to the pandemic, participants were asked to choose the circuit and the time/date to run, between April 18th and 30th. The Team chose the Stanley Park route, the epitome of Vancouver...